Anti-vaccine sentiment is alive and well, especially in the U.S. And it was evident in recent weeks as drugmakers revealed ...

Eli Lilly is continuing its recent pattern of tying disease awareness-raising efforts to major pop cultural moments. | Eli Lilly's latest high-profile crossovers—which include a starry TV partnership ...

As the researchers behind Pfizer and Astellas' Padcev and Merck's Keytruda have taken victory laps on the heels of the ...

Maryland is becoming the home away from home for British drugmaker AstraZeneca. | Maryland is becoming the home away from ...

Three years after striking up a Zymeworks licensing pact with an eye on challenging the status quo in HER2-positive cancers, ...

A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to ...

Texas Attorney General Ken Paxton filed a lawsuit Thursday on behalf of the state that takes aim at “false, misleading, and ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

The first of seven challenges for which Teva is seeking novel solutions revolves around human-predictive platforms for ...

Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...

With a fresh FDA endorsement for its drug plozasiran, California-based Arrowhead Pharmaceuticals has successfully broken ...

The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...